Trial Details
COMPLETEDBasic Information
| Clinical ID | c2351 |
|---|---|
| Identifier | NCT03629379 |
| Trial Title | Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Inflammatory Bowel Diseases|Psoriasis |
| Interventions | DRUG: Ustekinumab|DRUG: Vedolizumab |
Participant Information
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
|---|---|
| City | Leuven |
| Country/Region | Belgium |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE4 |
Time Information
| Start Date | 2019-01-22 |
|---|---|
| Primary Completion Date | 2021-01-01 |
| Completion Date | 2021-07-01 |